Regulatory matrix
91 published regulatory records. Each cites an official source and the date it was checked. A regulatory status says what one regulator recorded for one scope. It is not evidence of efficacy or safety, and one jurisdiction’s action does not apply in another. Pairs marked “No published record” mean only that WPF has published nothing for that jurisdiction. They do not mean no regulatory action exists or that a review is scheduled. Product or formulation is shown as “Not recorded” because the record does not capture it. The action label comes from the linked official source, not from the jurisdiction name.
414 rows
| Peptide | Jurisdiction | Regulator | Product or formulation | Scope | Action | Linked source | Date checked |
|---|---|---|---|---|---|---|---|
| AOD-9604 | European Union (EMA) | EMA | Not recorded | No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-08 |
| AOD-9604 | United States (FDA) | FDA | Not recorded | No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026. | No approval recorded | Drugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov | 2026-09-08 |
| Abaloparatide | European Union (EMA) | EMA | Not recorded | ELADYNOS (abaloparatide) is centrally authorised in the European Union for treatment of osteoporosis in postmenopausal women at increased risk of fracture. | Approval recorded | EMA EPAR — Eladynos (EMEA/H/C/005928)Linked source: www.ema.europa.eu | 2026-09-09 |
| Abaloparatide | United States (FDA) | FDA | Not recorded | TYMLOS (abaloparatide) is FDA-approved for treatment of postmenopausal women with osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy, and to increase bone density in men with osteoporosis at high risk for fracture or with the same treatment-history criteria. | Approval recorded | FDA Drugs@FDA NDA 208743 and TYMLOS Prescribing Information, revised August 2026Linked source: www.accessdata.fda.gov | 2026-09-09 |
| Afamelanotide | European Union — EMA | EMA | Not recorded | Scenesse (afamelanotide) is indicated for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). | Approval recorded | European Medicines Agency: Scenesse (afamelanotide)Linked source: www.ema.europa.eu | 2026-09-23 |
| Afamelanotide | United States — FDA | FDA | Not recorded | SCENESSE (afamelanotide) is indicated to increase pain-free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). | Approval recorded | FDA Orphan Drug Designations and Approvals: afamelanotide / SCENESSELinked source: www.accessdata.fda.gov | 2026-09-23 |
| BPC-157 | European Union (EMA) | EMA | Not recorded | No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-08 |
| BPC-157 | United States (FDA) | FDA | Not recorded | No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026. | No approval recorded | Drugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov | 2026-09-08 |
| Bivalirudin | European Union (EMA) | EMA | Not recorded | Angiox (bivalirudin) previously held an EU marketing authorization for adult PCI and urgent or early intervention in unstable angina or NSTEMI with specified concomitant antiplatelet therapy. The European Commission withdrew the authorization on 21 June 2018 at the marketing-authorization holder’s request for commercial discontinuation; the authorization is no longer valid. This is a withdrawal record, not a finding that the medicine lacked efficacy or safety. | No approval recorded | EMA EPAR — Angiox: withdrawn marketing authorisationLinked source: www.ema.europa.eu | 2026-09-09 |
| Bivalirudin | United States (FDA) | FDA | Not recorded | ANGIOMAX (bivalirudin) is FDA-approved as an intravenous anticoagulant for patients undergoing percutaneous coronary intervention, including patients with heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome. | Approval recorded | FDA Drugs@FDA NDA 020873 and ANGIOMAX Prescribing InformationLinked source: www.accessdata.fda.gov | 2026-09-09 |
| Bremelanotide | European Union — EMA | EMA | Not recorded | No centrally authorized EMA medicine containing bremelanotide was identified in the EMA medicines database as of 2026-09-23. Palatin Technologies licensed European rights for bremelanotide to Gedeon Richter in 2014; that licensing agreement was terminated in September 2016 with no EU marketing authorization resulting. Bremelanotide (Vyleesi) is FDA-approved in the United States only. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-23 |
| Bremelanotide | United States — FDA | FDA | Not recorded | VYLEESI (bremelanotide) is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty, and not due to a co-existing medical or psychiatric condition, relationship problems, or the effects of a medication or drug substance. Not indicated for HSDD in postmenopausal women or in men. | Approval recorded | FDA VYLEESI (bremelanotide injection) prescribing informationLinked source: www.accessdata.fda.gov | 2026-09-23 |
| CJC-1295 | European Union (EMA) | EMA | Not recorded | No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-08 |
| CJC-1295 | United States (FDA) | FDA | Not recorded | No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026. | No approval recorded | Drugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov | 2026-09-08 |
| Cagrilintide | European Union — EMA | EMA | Not recorded | No centrally authorized EMA medicine containing cagrilintide was identified in the EMA medicines database as of 2026-09-23. Cagrilintide remains investigational and has not completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-23 |
| Cagrilintide | United States — FDA | FDA | Not recorded | No FDA-approved product containing cagrilintide was identified in the FDA Drugs@FDA database as of 2026-09-23. Cagrilintide remains investigational, including in combination with semaglutide (CagriSema), and has not completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific. | No approval recorded | FDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov | 2026-09-23 |
| Carbetocin | Australia (TGA) | TGA | Not recorded | DURATOCIN carbetocin 100 microgram/mL injection is entered in the Australian Register of Therapeutic Goods for prevention of uterine atony and excessive bleeding following delivery in the product-specified obstetric setting. | Approval recorded | TGA ARTG — DURATOCIN carbetocin 100 microgram/mL injection vialLinked source: www.tga.gov.au | 2026-09-09 |
| Carbetocin | Canada (Health Canada) | Health Canada | Not recorded | DURATOCIN (carbetocin injection) is authorized in Canada for prevention of uterine atony and postpartum haemorrhage in the labeled obstetric setting. | Approval recorded | Health Canada Product Monograph — DURATOCIN (carbetocin injection)Linked source: health-products.canada.ca | 2026-09-09 |
| Desmopressin | United States (FDA — DDAVP) | FDA | Not recorded | DDAVP desmopressin acetate tablets are FDA-approved as antidiuretic replacement therapy in central diabetes insipidus and for management of temporary polyuria and polydipsia following head trauma or pituitary-region surgery, subject to current labeling. | Approval recorded | FDA Drugs@FDA — DDAVP NDA 019955Linked source: www.accessdata.fda.gov | 2026-09-09 |
| Desmopressin | United States (FDA — DESMODA) | FDA | Not recorded | DESMODA desmopressin acetate oral solution is FDA-approved for antidiuretic replacement therapy in patients with central diabetes insipidus (arginine vasopressin deficiency), according to its current product labeling. | Approval recorded | FDA Drugs@FDA — DESMODA NDA 219873Linked source: www.accessdata.fda.gov | 2026-09-09 |
| Elamipretide | European Union | EMA | Not recorded | EMA orphan designation is not marketing authorization; no EU marketing authorization was identified in the reviewed official record. | No approval recorded | EMA orphan designation EU/3/21/2430Linked source: www.ema.europa.eu | 2026-09-09 |
| Elamipretide | United States | FDA | Not recorded | Improve muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg. | Approval recorded | FDA accelerated approval announcementLinked source: www.fda.gov | 2026-09-09 |
| Epitalon | European Union (EMA) | EMA | Not recorded | No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-08 |
| Epitalon | United States (FDA) | FDA | Not recorded | No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026. | No approval recorded | Drugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov | 2026-09-08 |
| GHRP-2 | European Union | EMA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | EMA medicines portalLinked source: www.ema.europa.eu | 2026-09-09 |
| GHRP-2 | United States | FDA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | FDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov | 2026-09-09 |
| GHRP-6 | European Union | EMA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | EMA medicines portalLinked source: www.ema.europa.eu | 2026-09-09 |
| GHRP-6 | United States | FDA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | FDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov | 2026-09-09 |
| Glucagon | European Union — EMA | EMA | Not recorded | Baqsimi (glucagon nasal powder) is centrally authorized for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus. | Approval recorded | European Medicines Agency: Baqsimi (glucagon)Linked source: www.ema.europa.eu | 2026-09-23 |
| Glucagon | United States — FDA | FDA | Not recorded | GlucaGen (glucagon), specifically -- not glucagon as a class: indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes, and separately indicated as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adult patients only. | Approval recorded | FDA GlucaGen (glucagon) prescribing informationLinked source: www.accessdata.fda.gov | 2026-09-23 |
| Hexarelin | European Union | EMA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | EMA medicines portalLinked source: www.ema.europa.eu | 2026-09-09 |
| Hexarelin | United States | FDA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | FDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov | 2026-09-09 |
| Human chorionic gonadotropin (hCG) | European Union | EMA | Not recorded | Authorized products exist; exact product, indication, contraindications, and current labeling require owner verification. | Approval recorded | EMA medicines portalLinked source: www.ema.europa.eu | 2026-09-09 |
| Human chorionic gonadotropin (hCG) | United States | FDA | Not recorded | Authorized products exist; exact product, indication, contraindications, and current labeling require owner verification. | Approval recorded | FDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov | 2026-09-09 |
| Humanin | European Union — EMA | EMA | Not recorded | No centrally authorized EMA medicine containing humanin was identified in the EMA medicines database as of 2026-09-23. Humanin remains an investigational research-stage compound with no completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-23 |
| Humanin | United States — FDA | FDA | Not recorded | No FDA-approved product containing humanin was identified in the FDA Drugs@FDA database as of 2026-09-23. Humanin remains an investigational, laboratory- and animal-research-stage mitochondrial-derived peptide with no completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific. | No approval recorded | FDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov | 2026-09-23 |
| Ipamorelin | European Union (EMA) | EMA | Not recorded | No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-08 |
| Ipamorelin | United States (FDA) | FDA | Not recorded | No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026. | No approval recorded | Drugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov | 2026-09-08 |
| KPV | European Union (EMA) | EMA | Not recorded | No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-08 |
| KPV | United States (FDA) | FDA | Not recorded | No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026. | No approval recorded | Drugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov | 2026-09-08 |
| Kisspeptin | European Union — EMA | EMA | Not recorded | No centrally authorized EMA medicine containing kisspeptin was identified in the EMA medicines database as of 2026-09-23. Kisspeptin remains investigational with no completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-23 |
| Kisspeptin | United States — FDA | FDA | Not recorded | No FDA-approved product containing kisspeptin was identified in the FDA Drugs@FDA database as of 2026-09-23. Kisspeptin remains investigational, used chiefly as a research probe in reproductive-endocrinology studies, with no completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific. | No approval recorded | FDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov | 2026-09-23 |
| Kisspeptin-10 | European Union | EMA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | EMA medicines portalLinked source: www.ema.europa.eu | 2026-09-09 |
| Kisspeptin-10 | United States | FDA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | FDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov | 2026-09-09 |
| LL-37 | European Union | EMA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | EMA medicines portalLinked source: www.ema.europa.eu | 2026-09-09 |
| LL-37 | United States | FDA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | FDA Drugs@FDA / official FDA recordLinked source: www.accessdata.fda.gov | 2026-09-09 |
| Lanreotide | United States (FDA — SOMATULINE DEPOT) | FDA | Not recorded | SOMATULINE DEPOT is FDA-approved for long-term treatment of acromegalic patients meeting label criteria, treatment of unresectable well- or moderately differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival, and treatment of carcinoid syndrome to reduce short-acting somatostatin-analog rescue therapy. | Approval recorded | FDA Drugs@FDA — SOMATULINE DEPOT NDA 022074Linked source: www.accessdata.fda.gov | 2026-09-09 |
| Lanreotide | United States (FDA — lanreotide acetate) | FDA | Not recorded | FDA application NDA 215395 covers a currently marketed lanreotide acetate injection product in the strengths and indications specified by its approved labeling. | Approval recorded | FDA Drugs@FDA — Lanreotide acetate NDA 215395Linked source: www.accessdata.fda.gov | 2026-09-09 |
| Leuprolide | United States (FDA — LUPRON DEPOT) | FDA | Not recorded | LUPRON DEPOT leuprolide acetate is FDA-approved in product-specific depot formulations for palliative treatment of advanced prostate cancer and for other indications only as stated in the applicable current labeling. | Approval recorded | FDA Drugs@FDA — LUPRON DEPOT NDA 019943Linked source: www.accessdata.fda.gov | 2026-09-09 |
| Leuprolide | United States (FDA — LUPRON DEPOT-PED) | FDA | Not recorded | LUPRON DEPOT-PED is FDA-approved for treatment of pediatric patients with central precocious puberty under its age-, formulation-, dose-, and monitoring-specific labeling. | Approval recorded | FDA Drugs@FDA — LUPRON DEPOT-PED NDA 020263Linked source: www.accessdata.fda.gov | 2026-09-09 |
| Linaclotide | European Union — EMA | EMA | Not recorded | Constella (linaclotide) is centrally authorized for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults. | Approval recorded | European Medicines Agency: Constella (linaclotide)Linked source: www.ema.europa.eu | 2026-09-23 |
| Linaclotide | United States — FDA | FDA | Not recorded | LINZESS (linaclotide) is indicated for the treatment of: irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older; chronic idiopathic constipation (CIC) in adults; and functional constipation (FC) in pediatric patients 6 years of age and older. Contraindicated in patients less than 2 years of age (boxed warning: risk of serious dehydration). | Approval recorded | FDA LINZESS (linaclotide) prescribing informationLinked source: www.accessdata.fda.gov | 2026-09-23 |
| MOTS-c | European Union (EMA) | EMA | Not recorded | No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-08 |
| MOTS-c | United States (FDA) | FDA | Not recorded | No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026. | No approval recorded | Drugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov | 2026-09-08 |
| Mazdutide | China — NMPA | NMPA | Not recorded | Mazdutide injection is approved by China's National Medical Products Administration for chronic weight management in adults with obesity or overweight (NMPA approval date 2025-06-24; approval numbers 国药准字H20250036, 国药准字H20250037, 国药准字H20250038; the NMPA notice was published 2025-06-30). Indication wording (source: Innovent Biologics announcement of 2025-06-27, a company source and not the regulator; the announcement date is not the approval date): adjunct to a reduced-calorie diet and increased physical activity in adults with an initial BMI of 28 kg/m² or more (obesity), or 24 kg/m² or more (overweight) with at least one weight-related comorbid condition. Separately, a second indication, glycemic control in adults with type 2 diabetes, was announced as approved on 2025-09-19; that date rests on the company announcement and Chinese news reports, and no NMPA notice for it has been read. | Approval recorded | NMPA notice, published 2025-06-30: 2025年06月30日药品批准证明文件送达信息Linked source: www.nmpa.gov.cn | 2026-11-13 |
| Mazdutide | United States — FDA | FDA | Not recorded | No FDA-approved product containing mazdutide was identified in the FDA Drugs@FDA database as of 2026-09-23. Mazdutide is approved in China (see the China — NMPA entry on this profile) but remains investigational in the United States, where it has not completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific. | No approval recorded | FDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov | 2026-09-23 |
| Melanotan II | European Union | EMA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | EMA medicines portalLinked source: www.ema.europa.eu | 2026-09-09 |
| Melanotan II | United States | FDA | Not recorded | No FDA marketing approval identified. FDA separately reports limited safety information and potential risks for compounded Melanotan II. | Compounding action | FDA compounding safety-risk listLinked source: www.fda.gov | 2026-09-09 |
| Octreotide | United States (FDA — MYCAPSSA) | FDA | Not recorded | MYCAPSSA octreotide delayed-release capsules are FDA-approved for long-term maintenance treatment in acromegaly patients who responded to and tolerated octreotide or lanreotide, according to current labeling. | Approval recorded | FDA Drugs@FDA — MYCAPSSA NDA 208232Linked source: www.accessdata.fda.gov | 2026-09-09 |
| Octreotide | United States (FDA — SANDOSTATIN LAR DEPOT) | FDA | Not recorded | SANDOSTATIN LAR DEPOT is FDA-approved for long-term maintenance treatment in acromegaly after response and tolerance to subcutaneous octreotide, and for long-term treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIP-secreting tumors, under current label criteria. | Approval recorded | FDA Drugs@FDA — SANDOSTATIN LAR DEPOT NDA 021008Linked source: www.accessdata.fda.gov | 2026-09-09 |
| Oxytocin | United States (FDA — OXYTOCIN injection) | FDA | Not recorded | Oxytocin injection under NDA 018248 is FDA-approved as a prescription injectable product for its labeled obstetric uses and strengths. | Approval recorded | FDA Drugs@FDA — OXYTOCIN NDA 018248Linked source: www.accessdata.fda.gov | 2026-09-10 |
| Oxytocin | United States (FDA — PITOCIN) | FDA | Not recorded | PITOCIN oxytocin injection is FDA-approved for labeled obstetric uses, including medically indicated initiation or improvement of uterine contractions and control of postpartum uterine bleeding, subject to current labeling. | Approval recorded | FDA Drugs@FDA — PITOCIN NDA 018261Linked source: www.accessdata.fda.gov | 2026-09-10 |
| Pemvidutide | European Union — EMA | EMA | Not recorded | No centrally authorized EMA medicine containing pemvidutide was identified in the EMA medicines database as of 2026-09-23. Pemvidutide remains investigational with no completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-23 |
| Pemvidutide | United States — FDA | FDA | Not recorded | No FDA-approved product containing pemvidutide was identified in the FDA Drugs@FDA database as of 2026-09-23. Pemvidutide (ALT-801) remains an investigational compound in clinical development, with no completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific. | No approval recorded | FDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov | 2026-09-23 |
| Pramlintide | European Union — EMA | EMA | Not recorded | No centrally authorized EMA medicine containing pramlintide was identified in the EMA medicines database as of 2026-09-23. Pramlintide (SYMLIN) is FDA-approved in the United States only. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-23 |
| Pramlintide | United States — FDA | FDA | Not recorded | SYMLIN (pramlintide) is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. Labeled pediatric use: safety and effectiveness in pediatric patients have not been established. | Approval recorded | FDA SYMLIN (pramlintide acetate) prescribing informationLinked source: www.accessdata.fda.gov | 2026-09-23 |
| Retatrutide | European Union (EMA) | EMA | Not recorded | No centrally authorised retatrutide medicine is listed. An EMA paediatric investigation plan is a development requirement and does not constitute marketing authorisation. | No approval recorded | EMA medicines database and retatrutide paediatric investigation planLinked source: www.ema.europa.eu | 2026-09-08 |
| Retatrutide | United States (FDA) | FDA | Not recorded | Retatrutide remains investigational and is not an FDA-approved drug. Substance identity records, clinical-trial status, or development announcements do not constitute marketing approval. | No approval recorded | FDA — concerns with unapproved GLP-1 drugs used for weight lossLinked source: www.fda.gov | 2026-09-08 |
| Selank | European Union | EMA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | EMA medicines portalLinked source: www.ema.europa.eu | 2026-09-09 |
| Selank | United States | FDA | Not recorded | No FDA marketing approval identified. FDA separately reports limited safety information and potential risks for compounded Selank. | Compounding action | FDA compounding safety-risk listLinked source: www.fda.gov | 2026-09-09 |
| Semaglutide | European Union (EMA) | EMA | Not recorded | Semaglutide is centrally authorised in the European Union in product-specific forms: Ozempic and Rybelsus for defined type 2 diabetes populations, and Wegovy for weight management in defined adults and adolescents. The applicable population, formulation, dose, contraindications, and current product information remain controlling. | Approval recorded | EMA EPARs — Wegovy, Ozempic and RybelsusLinked source: www.ema.europa.eu | 2026-09-08 |
| Semaglutide | United States (FDA) | FDA | Not recorded | Current FDA labeling for Wegovy identifies semaglutide formulations for defined cardiovascular-risk reduction and chronic weight-reduction populations; Wegovy injection is also approved for defined adults with noncirrhotic MASH and moderate-to-advanced fibrosis under accelerated approval. Product, formulation, age, comorbidity, and indication restrictions apply. | Approval recorded | FDA Wegovy Prescribing Information, revised June 2026Linked source: www.accessdata.fda.gov | 2026-09-08 |
| Semax | European Union | EMA | Not recorded | No marketing authorization identified in the cited official portal; absence is machine-staged and requires accountable recheck. | No approval recorded | EMA medicines portalLinked source: www.ema.europa.eu | 2026-09-09 |
| Semax | United States | FDA | Not recorded | No FDA marketing approval identified. FDA separately reports limited safety information and potential risks for compounded Semax. | Compounding action | FDA compounding safety-risk listLinked source: www.fda.gov | 2026-09-09 |
| TB-500 | European Union (EMA) | EMA | Not recorded | No centrally authorized EMA medicine for the named compound was identified in the EMA medicines database as of 8 September 2026. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-08 |
| TB-500 | United States (FDA) | FDA | Not recorded | No FDA-approved drug product or therapeutic indication for the named compound was identified in Drugs@FDA as of 8 September 2026. | No approval recorded | Drugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov | 2026-09-08 |
| Teduglutide | European Union — EMA | EMA | Not recorded | Revestive (teduglutide) is indicated for the treatment of patients 4 months corrected gestational age and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. (Per the current SmPC Section 4.1; supersedes the older '1 year and above' figure still shown in the EMA overview page's summary info box as of this research.) | Approval recorded | European Medicines Agency: Revestive (teduglutide)Linked source: www.ema.europa.eu | 2026-09-23 |
| Teduglutide | United States — FDA | FDA | Not recorded | GATTEX (teduglutide) is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support. | Approval recorded | FDA GATTEX (teduglutide) prescribing informationLinked source: www.accessdata.fda.gov | 2026-09-23 |
| Teriparatide | United States (FDA — BONSITY) | FDA | Not recorded | BONSITY teriparatide is FDA-approved as a prescription subcutaneous teriparatide product for its labeled osteoporosis indications and populations. | Approval recorded | FDA Drugs@FDA — BONSITY NDA 211939Linked source: www.accessdata.fda.gov | 2026-09-10 |
| Teriparatide | United States (FDA — FORTEO) | FDA | Not recorded | FORTEO teriparatide is FDA-approved for labeled osteoporosis indications in specified patients at high fracture risk; the current product, strength, route, duration guidance, warnings, and patient-selection language control. | Approval recorded | FDA Drugs@FDA — FORTEO NDA 021318Linked source: www.accessdata.fda.gov | 2026-09-10 |
| Tesamorelin | United States | FDA | Not recorded | Reduction of excess abdominal fat in adult patients with HIV and lipodystrophy. | Approval recorded | Drugs@FDA BLA 022505 and EGRIFTA prescribing informationLinked source: www.accessdata.fda.gov | 2026-09-08 |
| Thymosin alpha-1 | European Union (EMA) | EMA | Not recorded | No centrally authorized EMA thymosin alpha-1 or thymalfasin medicine was identified in the EMA medicines database as of 8 September 2026. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-08 |
| Thymosin alpha-1 | United States (FDA) | FDA | Not recorded | No FDA-approved thymosin alpha-1 or thymalfasin drug product or therapeutic indication was identified in Drugs@FDA as of 8 September 2026. | No approval recorded | Drugs@FDA: FDA-Approved DrugsLinked source: www.accessdata.fda.gov | 2026-09-08 |
| Thymosin beta-4 | European Union — EMA | EMA | Not recorded | No centrally authorized EMA medicine containing thymosin beta-4 was identified in the EMA medicines database as of 2026-09-23. Thymosin beta-4 remains an unapproved, investigational compound with no completed EU marketing review. Absence of a record in this search is not proof that no authorization exists via another regulatory pathway (e.g. national member-state authorization outside the centralized procedure). Status remains jurisdiction-, product-, and date-specific. | No approval recorded | European Medicines Agency medicines databaseLinked source: www.ema.europa.eu | 2026-09-23 |
| Thymosin beta-4 | United States — FDA | FDA | Not recorded | No FDA-approved product containing thymosin beta-4 was identified in the FDA Drugs@FDA database as of 2026-09-23. Thymosin beta-4 remains an unapproved, investigational compound with no completed FDA marketing review. Absence of a record in this search is not proof that no authorization exists under a different product name or application. Status remains product- and date-specific. | No approval recorded | FDA Drugs@FDA databaseLinked source: www.accessdata.fda.gov | 2026-09-23 |
| Tirzepatide | European Union (EMA) | EMA | Not recorded | Mounjaro is centrally authorised in the European Union for defined type 2 diabetes and weight-management populations, subject to the current product information. | Approval recorded | EMA EPAR — MounjaroLinked source: www.ema.europa.eu | 2026-09-08 |
| Tirzepatide | United States (FDA) | FDA | Not recorded | Mounjaro is approved for defined patients with type 2 diabetes; Zepbound is approved for chronic weight management in defined adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Product- and label-specific restrictions apply. | Approval recorded | FDA Drugs@FDA — tirzepatide (Mounjaro and Zepbound)Linked source: www.accessdata.fda.gov | 2026-09-08 |
| Vasopressin | Canada (Health Canada — Vasopressin Injection USP DIN 02139502) | Health Canada | Not recorded | Canadian-authorized product: Vasopressin Injection, USP, 20 units/mL, for intramuscular or subcutaneous administration (DIN 02139502, Fresenius Kabi Canada Ltd). Its Health Canada product monograph (dated 2022-03-28) states it is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows, and in diabetes insipidus. Separate from this authorization, a Health Canada notice (last updated 2026-03-04) permits exceptional, temporary importation of a different, US-authorized product, Vasopressin Injection, USP, 20 units/mL for IV infusion (Fresenius Kabi USA, NDC 63323-930-00, listed under a US product code and not a Canadian DIN), during a shortage of the Canadian product. | Approval recorded | Health Canada Drug Product Database: VASOPRESSIN INJECTION, USP, DIN 02139502 (Fresenius Kabi Canada Ltd), status MarketedLinked source: health-products.canada.ca | 2026-11-13 |
| Vasopressin | United States (FDA — VASOSTRICT) | FDA | Not recorded | VASOSTRICT vasopressin intravenous solution is FDA-approved to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines, according to current labeling. | Approval recorded | FDA Drugs@FDA — VASOSTRICT NDA 204485Linked source: www.accessdata.fda.gov | 2026-09-10 |
| Ziconotide | European Union — EMA | EMA | Not recorded | Ziconotide (Prialt) is indicated for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia. | Approval recorded | European Medicines Agency: Prialt (ziconotide)Linked source: www.ema.europa.eu | 2026-09-23 |
| Ziconotide | United States — FDA | FDA | Not recorded | PRIALT (ziconotide intrathecal infusion) is indicated for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine. Labeled pediatric use: safety and effectiveness in pediatric patients have not been established. | Approval recorded | FDA PRIALT (ziconotide) prescribing informationLinked source: www.accessdata.fda.gov | 2026-09-23 |
| AOD-9604 | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| AOD-9604 | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| AOD-9604 | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| AOD-9604 | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| AOD-9604 | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| AOD-9604 | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Abaloparatide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Abaloparatide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Abaloparatide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Abaloparatide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Abaloparatide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Abaloparatide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Afamelanotide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Afamelanotide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Afamelanotide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Afamelanotide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Afamelanotide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Afamelanotide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| BPC-157 | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| BPC-157 | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| BPC-157 | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| BPC-157 | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| BPC-157 | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| BPC-157 | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Bivalirudin | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Bivalirudin | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Bivalirudin | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Bivalirudin | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Bivalirudin | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Bivalirudin | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Bremelanotide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Bremelanotide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Bremelanotide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Bremelanotide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Bremelanotide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Bremelanotide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| CJC-1295 | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| CJC-1295 | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| CJC-1295 | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| CJC-1295 | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| CJC-1295 | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| CJC-1295 | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Cagrilintide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Cagrilintide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Cagrilintide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Cagrilintide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Cagrilintide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Cagrilintide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Carbetocin | United States | FDA | Not recorded | Not recorded | No published record | — | — |
| Carbetocin | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Carbetocin | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Carbetocin | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Carbetocin | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Carbetocin | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Desmopressin | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Desmopressin | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Desmopressin | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Desmopressin | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Desmopressin | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Desmopressin | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Desmopressin | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Dulaglutide | United States | FDA | Not recorded | Not recorded | No published record | — | — |
| Dulaglutide | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Dulaglutide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Dulaglutide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Dulaglutide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Dulaglutide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Dulaglutide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Dulaglutide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Elamipretide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Epitalon | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Epitalon | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Epitalon | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Epitalon | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Epitalon | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Epitalon | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Exenatide | United States | FDA | Not recorded | Not recorded | No published record | — | — |
| Exenatide | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Exenatide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Exenatide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Exenatide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Exenatide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Exenatide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Exenatide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| GHK-Cu | United States | FDA | Not recorded | Not recorded | No published record | — | — |
| GHK-Cu | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| GHK-Cu | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| GHK-Cu | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| GHK-Cu | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| GHK-Cu | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| GHK-Cu | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| GHK-Cu | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| GHRP-2 | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| GHRP-2 | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| GHRP-2 | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| GHRP-2 | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| GHRP-2 | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| GHRP-2 | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| GHRP-6 | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| GHRP-6 | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| GHRP-6 | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| GHRP-6 | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| GHRP-6 | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| GHRP-6 | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Glucagon | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Glucagon | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Glucagon | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Glucagon | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Glucagon | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Glucagon | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Hexarelin | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Hexarelin | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Hexarelin | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Hexarelin | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Hexarelin | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Hexarelin | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Human chorionic gonadotropin (hCG) | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Human chorionic gonadotropin (hCG) | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Human chorionic gonadotropin (hCG) | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Human chorionic gonadotropin (hCG) | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Human chorionic gonadotropin (hCG) | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Human chorionic gonadotropin (hCG) | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Humanin | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Humanin | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Humanin | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Humanin | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Humanin | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Humanin | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Ipamorelin | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Ipamorelin | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Ipamorelin | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Ipamorelin | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Ipamorelin | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Ipamorelin | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| KPV | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| KPV | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| KPV | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| KPV | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| KPV | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| KPV | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin-10 | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin-10 | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin-10 | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin-10 | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin-10 | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Kisspeptin-10 | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| LL-37 | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| LL-37 | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| LL-37 | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| LL-37 | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| LL-37 | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| LL-37 | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Lanreotide | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Lanreotide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Lanreotide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Lanreotide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Lanreotide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Lanreotide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Lanreotide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Leuprolide | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Leuprolide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Leuprolide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Leuprolide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Leuprolide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Leuprolide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Leuprolide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Linaclotide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Linaclotide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Linaclotide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Linaclotide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Linaclotide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Linaclotide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Liraglutide | United States | FDA | Not recorded | Not recorded | No published record | — | — |
| Liraglutide | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Liraglutide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Liraglutide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Liraglutide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Liraglutide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Liraglutide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Liraglutide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| MOTS-c | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| MOTS-c | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| MOTS-c | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| MOTS-c | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| MOTS-c | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| MOTS-c | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Mazdutide | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Mazdutide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Mazdutide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Mazdutide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Mazdutide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Mazdutide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Melanotan II | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Melanotan II | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Melanotan II | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Melanotan II | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Melanotan II | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Melanotan II | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Octreotide | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Octreotide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Octreotide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Octreotide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Octreotide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Octreotide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Octreotide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Oxytocin | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Oxytocin | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Oxytocin | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Oxytocin | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Oxytocin | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Oxytocin | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Oxytocin | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Pemvidutide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Pemvidutide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Pemvidutide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Pemvidutide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Pemvidutide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Pemvidutide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Pramlintide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Pramlintide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Pramlintide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Pramlintide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Pramlintide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Pramlintide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Retatrutide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Retatrutide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Retatrutide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Retatrutide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Retatrutide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Retatrutide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Selank | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Selank | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Selank | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Selank | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Selank | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Selank | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Semaglutide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Semax | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Semax | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Semax | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Semax | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Semax | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Semax | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Survodutide | United States | FDA | Not recorded | Not recorded | No published record | — | — |
| Survodutide | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Survodutide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Survodutide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Survodutide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Survodutide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Survodutide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Survodutide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| TB-500 | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| TB-500 | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| TB-500 | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| TB-500 | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| TB-500 | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| TB-500 | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Teduglutide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Teduglutide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Teduglutide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Teduglutide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Teduglutide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Teduglutide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Teriparatide | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Teriparatide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Teriparatide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Teriparatide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Teriparatide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Teriparatide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Teriparatide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Tesamorelin | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Tesamorelin | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Tesamorelin | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Tesamorelin | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Tesamorelin | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Tesamorelin | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Tesamorelin | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Thymosin alpha-1 | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Thymosin alpha-1 | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Thymosin alpha-1 | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Thymosin alpha-1 | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Thymosin alpha-1 | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Thymosin alpha-1 | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Thymosin beta-4 | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Thymosin beta-4 | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Thymosin beta-4 | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Thymosin beta-4 | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Thymosin beta-4 | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Thymosin beta-4 | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Tirzepatide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Tirzepatide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Tirzepatide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Tirzepatide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Tirzepatide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Tirzepatide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Vasopressin | European Union | EMA | Not recorded | Not recorded | No published record | — | — |
| Vasopressin | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Vasopressin | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Vasopressin | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Vasopressin | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Vasopressin | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |
| Ziconotide | United Kingdom | MHRA | Not recorded | Not recorded | No published record | — | — |
| Ziconotide | Canada | Health Canada | Not recorded | Not recorded | No published record | — | — |
| Ziconotide | Australia | TGA | Not recorded | Not recorded | No published record | — | — |
| Ziconotide | Japan | PMDA / MHLW | Not recorded | Not recorded | No published record | — | — |
| Ziconotide | China | NMPA | Not recorded | Not recorded | No published record | — | — |
| Ziconotide | Sport (WADA) | WADA | Not recorded | Not recorded | No published record | — | — |